Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
ZA200609583B - Pharmaceutical compositions comprising higher primary allphatic alcohols and HMG CoA reductase Inhibitor and process of preparation thereof - Google Patents
[go: Go Back, main page]

ZA200609583B - Pharmaceutical compositions comprising higher primary allphatic alcohols and HMG CoA reductase Inhibitor and process of preparation thereof - Google Patents

Pharmaceutical compositions comprising higher primary allphatic alcohols and HMG CoA reductase Inhibitor and process of preparation thereof

Info

Publication number
ZA200609583B
ZA200609583B ZA200609583A ZA200609583A ZA200609583B ZA 200609583 B ZA200609583 B ZA 200609583B ZA 200609583 A ZA200609583 A ZA 200609583A ZA 200609583 A ZA200609583 A ZA 200609583A ZA 200609583 B ZA200609583 B ZA 200609583B
Authority
ZA
South Africa
Prior art keywords
preparation
pharmaceutical compositions
coa reductase
reductase inhibitor
hmg coa
Prior art date
Application number
ZA200609583A
Other languages
English (en)
Inventor
Jain Rajesh
Jindal Kour Chand
Singh Sukhjeet
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of ZA200609583B publication Critical patent/ZA200609583B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200609583A 2004-01-20 2005-01-19 Pharmaceutical compositions comprising higher primary allphatic alcohols and HMG CoA reductase Inhibitor and process of preparation thereof ZA200609583B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN99DE2004 2004-01-20

Publications (1)

Publication Number Publication Date
ZA200609583B true ZA200609583B (en) 2008-08-27

Family

ID=34779368

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200609583A ZA200609583B (en) 2004-01-20 2005-01-19 Pharmaceutical compositions comprising higher primary allphatic alcohols and HMG CoA reductase Inhibitor and process of preparation thereof

Country Status (9)

Country Link
US (1) US20080247962A1 (sr)
EP (1) EP1755587A1 (sr)
AP (1) AP2006003833A0 (sr)
AU (1) AU2005205165B9 (sr)
CA (1) CA2553988A1 (sr)
EA (1) EA009918B1 (sr)
RS (1) RS20060436A (sr)
WO (1) WO2005067921A1 (sr)
ZA (1) ZA200609583B (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
WO2006054308A2 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5515486A (en) * 1994-12-16 1996-05-07 International Business Machines Corporation Method, apparatus and memory for directing a computer system to display a multi-axis rotatable, polyhedral-shape panel container having front panels for displaying objects
US6157383A (en) * 1998-06-29 2000-12-05 Microsoft Corporation Control polyhedra for a three-dimensional (3D) user interface
US6225354B1 (en) * 1999-06-21 2001-05-01 Cholesterol Control Laboratories, Inc. High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof
US6197832B1 (en) * 1999-09-14 2001-03-06 Harlan Lee Sorkin, Jr. Composition for reducing serum cholesterol levels
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ

Also Published As

Publication number Publication date
RS20060436A (sr) 2008-11-28
WO2005067921A1 (en) 2005-07-28
EP1755587A1 (en) 2007-02-28
CA2553988A1 (en) 2005-07-28
EA009918B1 (ru) 2008-04-28
AU2005205165A1 (en) 2005-07-28
AP2006003833A0 (en) 2006-12-31
US20080247962A1 (en) 2008-10-09
WO2005067921A8 (en) 2005-11-03
EA200602201A1 (ru) 2007-04-27
AU2005205165B2 (en) 2008-04-24
AU2005205165B9 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
EE200200052A (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid
IL180517A0 (en) Novel statin pharmaceutical compositions and related methods of treatment
HRP20041238A2 (en) Use of cetp inhibitors and optionally hmg coa redught hyaluronic acid formulation
IL191998A (en) Pharmaceutical compounds and compositions of multicyclic amino acid history and their use
IL178250A0 (en) Synthesis of boronic ester and acid compounds
HUP0302955A3 (en) Hmg-coa reductase inhibitors, pharmaceutical compositions containing them and their use for treatment of cholesterol related diseases
AU2003245313A1 (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
PL374364A1 (en) Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors
IL173726A (en) Pharmaceutical compositions containing n-n-dihaloamino acids and their uses
ZA200609584B (en) Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
ZA200508204B (en) Pharmaceutical composition of atorvastatin
IL178475A0 (en) Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof
ZA200609583B (en) Pharmaceutical compositions comprising higher primary allphatic alcohols and HMG CoA reductase Inhibitor and process of preparation thereof
EP1968609A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS
ZA200701916B (en) Novel statin pharmaceutical compositions and related methods of treatment
EP1871396A4 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS WITH AN HMG COA REDUCTASE INHIBITOR
EP1807122A4 (en) MEDICAL AEROSOL FORMULATIONS AND METHOD FOR SYNTHETIZING INGREDIENTS THEREFOR
AP2006003834A0 (en) Novel compositions comprising higher primary alcohols and nicottinic acid and process of preparationthereof
GB2418855B (en) Use of ethyl lactate as an excipient for pharmaceutical compositions
IL165452A0 (en) Use of CETP inhibitors and antihypertensive agentsas well as optionally HMG COA reductase inhibitor s
HK1107252A (en) Novel statin pharmaceutical compositions and related methods of treatment
HK1104915A (en) Pharmaceutical compositions comprising fenofibrate and atorvastatin
HK1104918A (en) Pharmaceutical compositions comprising fenofibrate and atorvastatin
AU2002303518A1 (en) Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents